Participated · Equity · Dec 2021

Kudo Money builds Unomi identity passports, a decentralised scoring protocol that aggregates on-chain activity across Ethereum, Polygon, BSC and Solana to produce programmable scores (0–100) like Credit, Airdrop, Hodler and Power‑user. These passports let users batch wallets, sync multi‑chain activity, and enable protocols to profile users for rewards, undercollateralized lending, airdrops and improved UX. The company says scores will help DeFi protocols assess creditworthiness and allow addresses with higher reputation to access borrowing, airdrops and farming opportunities. Kudo is developing an ecosystem of Web3 products (including Unomi and Bitquity) aimed at mainstream crypto adoption. Financially, Kudo closed a $4 million strategic funding round to accelerate development of the passport ecosystem. The company plans to decentralise identity infrastructure by launching a native token, $KUDO, with a public sale planned for Q1 next year.

Participated · Seed · Jan 2021

Biconomy offers plug-and-play APIs that relay transactions between layer 1 blockchains and layer 2 systems to make developing decentralized apps easier. The protocol enables gasless transactions and instant cross-chain transfers and is used by more than 70 Web3, DeFi and NFT dapps. To date it has processed more than 8.2 million transactions across Ethereum, Polygon, Binance Smart Chain, Avalanche and Moonriver. Financially, Biconomy raised $11.5 million through a public sale of its native token BICO on CoinList. The company previously raised $9 million in July from investors including Coinbase Ventures and Huobi Innovation Labs. The CoinList sale attracted more than 860,000 registrations and added 12,000 new token holders. Biconomy provides multichain transaction infrastructure and plug-and-play SDKs and APIs to simplify blockchain onboarding and user transactions. Its offerings enable gasless transactions, gas payments in ERC20 tokens and instant cross-chain transactions to reduce friction for end users. The company aims to create seamless multichain experiences that make Web 3.0 applications easier to use and help onboard more users. Biconomy says it has processed more than 3.6 million mainnet transactions representing $572 million in transaction volume across more than 30 live integrations on major chains. The startup plans to scale its products and ensure its infrastructure is ready for next-generation Web 3.0 applications. Founded in 2019, Biconomy has seen solid growth and has raised $10.5 million to date. Biconomy is a blockchain infrastructure provider that helps developers build simpler decentralized applications (dApps) by paying gas fees on their behalf through transaction relayers. Developers reimburse Biconomy via Ethereum or other payment modes. Founded in March 2019 by Aniket Jindal, Ahmed Al-Balaghi, and Sachin Tomar, the company aims to make dApp adoption as simple as conventional apps. It plans to use its newly raised capital to strengthen and grow its team, accelerate product and business development, and to launch Biconomy V2. CEO Ahmed Al-Balaghi has argued that charging users gas fees for every interaction is a key barrier to mass adoption of web3.

Participated · Equity · Jul 2015

Oncobiologics is a Cranbury, NJ-based biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. The company is advancing a pipeline of 11 biosimilar products, two of which are currently in clinical development. It is led by founder and CEO Pankaj Mohan, Ph.D., and operates from a 50,000 sq. ft. fully-integrated R&D and manufacturing facility in Cranbury, NJ. Oncobiologics' core technology is its proprietary BioSymphony™ biosimilar platform. The company intends to use the financing proceeds to continue development and expansion of the BioSymphony platform and to advance its preclinical and clinical programs. The recent financing strengthens its balance sheet to support those development activities. Oncobiologics is a privately held biopharmaceutical company focused on developing biosimilars and next-generation biotherapeutics. The company operates from a 40,000 sq. ft. fully integrated R&D and manufacturing facility in Cranbury, New Jersey. It was formed by a team of industry experts from firms including Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer. Oncobiologics is advancing a pipeline of biosimilars and novel biologic therapies and aims to continue executing its business and technical plans. The company has secured strategic backing to support its development and commercialization efforts. Financial details beyond the strategic investment announcement were not disclosed.